Table 3.
Operating room turnover time and cost-effective analyses of the sugammadex and neostigmine groups (matched cohort).
| Neostigmine n = 892 |
Sugammadex n = 892 |
Adjusted Mean Difference † | 95% CI | p | |||
|---|---|---|---|---|---|---|---|
| Operating room turnover time, min | |||||||
| Time to extubation | 6.6 | 6.3 | 6.0 | 5.3 | −0.10 | −0.17, −0.03 | 0.0032 |
| Time to leave the OR | 9.0 | 6.7 | 8.5 | 6.2 | −0.07 | −0.13, −0.02 | 0.0108 |
| Time to arrive at the PACU | 18.9 | 6.6 | 18.3 | 6.0 | −0.04 | −0.06, −0.01 | 0.0088 |
| Length of PACU stay | 48.0 | 9.3 | 48.8 | 13.8 | 0.02 | 0, 0.03 | 0.0785 |
| Duration of surgery | 107.0 | 73.3 | 101.9 | 77.6 | −0.05 | −0.11, 0.01 | 0.1201 |
| Duration of anesthesia | 158.5 | 82.5 | 151.6 | 89.6 | −0.05 | −0.09, 0 | 0.0406 |
| Costs, USD | |||||||
| Personnel ‡ | 27.2 | 18.7 | 25.8 | 16.3 | −0.06 | −0.11, −0.01 | 0.0130 |
| Time to extubation | 19.0 | 18.6 | 17.4 | 15.6 | −0.10 | −0.17, −0.03 | 0.0032 |
| PACU | 8.2 | 1.6 | 8.4 | 4.1 | 0.03 | 0.01, 0.05 | 0.0039 |
| Neuromuscular blocking and reversal agents | 23.4 | 7.7 | 186.2 | 44.7 | 2.07 | 2.05, 2.09 | <0.0001 |
| Total § | 50.6 | 21.4 | 212.0 | 49.5 | 1.43 | 1.40, 1.45 | <0.0001 |
Values were mean ± standard deviation. CI = confidence interval; OR = operating room; PACU = post-anesthesia care unit; USD = United States dollar. † Adjusted for age, sex, body mass index, and rocuronium dose. ‡ Personnel costs = time to extubation costs + PACU costs; § Total costs = personnel costs + costs of neuromuscular blocking and reversal agents